US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.610
- +0.110+4.40%
Close Nov 21 16:00 ET
- 2.530
- -0.080-3.07%
Post 16:43 ET
3.88MMarket Cap0.04P/E (TTM)
2.730High2.360Low101.64KVolume2.420Open2.500Pre Close264.50KTurnover6.96%Turnover RatioLossP/E (Static)1.49MShares71.85052wk High1.29P/B3.81MFloat Cap1.83552wk Low--Dividend TTM1.46MShs Float1590.000Historical High--Div YieldTTM14.80%Amplitude1.835Historical Low2.602Avg Price1Lot Size
About Tharimmune Company
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or \"uncontrollable itching\" in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Company Profile
SymbolTHAR
Company NameTharimmune
Listing DateJan 12, 2022
Founded2017
CEOMr. Randy Milby
MarketNASDAQ
Employees3
Fiscal Year Ends12-31
Address1200 Route 22 East,Suite 2000
CityBridgewater
ProvinceNew Jersey
CountryUnited States of America
Zip Code08807
Phone1-908-955-3140
Websitehttp://tharimmune.com
Company Executives
- Name
- Position
- Salary
- Randy Milby
- Chief Executive Officer and Chairman of the Board
- 742.42K
- Thomas P. Hess
- Chief Financial Officer and Principal Accounting Officer
- --
- Sireesh Appajosyula
- Director and Chief Operating Officer
- 8.48K
- Leonard L. Mazur
- Independent Director
- 34.43K
- Dr. Lynne A. Bui, M.D.
- Independent Director
- 41.57K
- Kelly J. Anderson
- Independent Director
- 46.17K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data